AT Activate, provides one-stop, data-driven media strategy, planning, buying and analytics services to ensure that healthcare media campaigns hit their targets and deliver measurable business success for clients.
A day after the regulator denied approval of Lykos’ MDMA-assisted PTSD therapy, a medical journal pulled three studies related to the use of the psychedelic in the indication.
Humacyte’s stock price dropped 18% in after-hours trading Friday after the company announced the FDA requires additional time to review its Biologic License Application. No reason was given for the delay or an updated decision date.
Ascendis’s Yorvipath, will become the only approved treatment for the condition, called hypoparathyroidism, in the United States after rival Takeda stops manufacturing its injection, Natpara, at the end of this year due to supply issues.
Pfizer said on Monday its respiratory syncytial virus (RSV) vaccine Abrysvo generated a strong immune response in a late-stage study of four groups of adults aged 18 and older with a compromised immune system.
Keytruda is set to continue dominating the sales landscape in 2024 and beyond, but the fast-rising GLP-1 drugs led by Ozempic will reshape the top 10 ranks by the end of the decade.